These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23544717)

  • 1. A review of current and emerging therapeutic strategies in multiple sclerosis.
    Tullman MJ
    Am J Manag Care; 2013 Feb; 19(2 Suppl):S21-7. PubMed ID: 23544717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
    Berger JR
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the symptoms of multiple sclerosis: a multimodal approach.
    Crayton HJ; Rossman HS
    Clin Ther; 2006 Apr; 28(4):445-60. PubMed ID: 16750459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving management of optic neuritis and multiple sclerosis.
    Arnold AC
    Am J Ophthalmol; 2005 Jun; 139(6):1101-8. PubMed ID: 15953446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.
    Panitch H; Applebee A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1511-21. PubMed ID: 21635193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic management in multiple sclerosis.
    Samkoff LM; Goodman AD
    Neurol Clin; 2011 May; 29(2):449-63. PubMed ID: 21439453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil.
    Niepel G; Bibani RH; Vilisaar J; Langley RW; Bradshaw CM; Szabadi E; Constantinescu CS
    Neuropharmacology; 2013 Jan; 64():380-8. PubMed ID: 22766394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
    Sørensen PS
    Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlapping and distinct mechanisms of action of multiple sclerosis therapies.
    Graber JJ; McGraw CA; Kimbrough D; Dhib-Jalbut S
    Clin Neurol Neurosurg; 2010 Sep; 112(7):583-91. PubMed ID: 20627553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
    Goodin DS; Bates D
    Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutics in multiple sclerosis management: clinical applications.
    Leist T; Hunter SF; Kantor D; Markowitz C
    Am J Med; 2014 Jan; 127(1):S2. PubMed ID: 24384114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic indications for acute episodes of multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):988-95. PubMed ID: 11787365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for multiple sclerosis: progress and prospects.
    Palmer AM
    Curr Opin Investig Drugs; 2009 May; 10(5):407-17. PubMed ID: 19431073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.